Search
Methazolamide
go.drugbank.com/drugs/DB00703ApprovedA carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.
Pramiracetam
go.drugbank.com/drugs/DB13247ApprovedPramiracetam has been studied for the use in Alzheimer's disease and as an adjunct treatment to restore cognitive functioning post-electroconvulsive therapy in severe depression [L5470]. … It was also previously approved in the United States with orphan drug designation [L1469].
Romlusevimab
go.drugbank.com/drugs/DB16494InvestigationalRomlusevimab (BRII-198) was under investigation in clinical trials (NCT04479644 and NCT04691180) to treat COVID-19, focusing on its safety, tolerability, and pharmacokinetics.
Progabide
go.drugbank.com/drugs/DB00837ExperimentalProgabide is an analog and prodrug of gamma-aminobutyric acid. It is commonly used in the treatment of epilepsy. It has agonistic activity for both the GABAA and GABAB receptors. … In clinical trials, progabide has been investigated for Parkinson's disease, schizophrenia, clinical depression and anxiety disorder; its therapeutic effectiveness in these conditions is not fully elucidated
MN-246
go.drugbank.com/drugs/DB05981ExperimentalMN-246 is a novel ß3-adrenergic receptor agonist developed for the treatment of urinary incontinence by MediciNova Inc.
Inaxaplin
go.drugbank.com/drugs/DB21521InvestigationalInaxaplin has a monoisotopic molecular weight of 417.13 Da. … Inaxaplin is under investigation in clinical trial NCT06794996 (Phase 2b Open-label Study of Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease).
Alimemazine
go.drugbank.com/drugs/DB01246ApprovedVet approvedWithdrawnA phenothiazine derivative that is used as an antipruritic.
XmAb 2513
go.drugbank.com/drugs/DB06324InvestigationalXmAb 2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types.
MPI-674
go.drugbank.com/drugs/DB05749ExperimentalMPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability profile. … AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen.